CJC-1295

CJC-1295 is a modified fragment of growth hormone releasing hormone, engineered to survive in the bloodstream far longer than the natural version. It is the standard partner to ipamorelin, on the logic that one compound raises the signal and the other amplifies the pulse.

Two quite different molecules are sold under this one name, which is the single most useful thing to understand before reading anything else about it.

Why people are talking about it#

Because unlike most compounds in this family, it has published human data showing it does what it claims mechanically. A single dose produced sustained increases in growth hormone and IGF-1 for several days in healthy adults, which is a real and measured effect rather than an extrapolation.

The duration is the other reason. Most growth hormone releasers produce a pulse lasting minutes. The DAC version of this one binds to albumin in the blood and keeps signalling raised for days from one injection.

What people take it for#

Lean muscle, fat loss, recovery and sleep. It sits at the centre of most growth hormone peptide protocols.

Body composition#

The claim is more lean mass and less fat without training changing. The mechanism is a sustained increase in growth hormone and in IGF-1, the downstream hormone through which most of growth hormone's tissue effects are thought to act.

In practice that describes the body being told, continuously rather than in pulses, to build and to mobilise stored fat. The hormone change has been measured in healthy adults.

Sleep and recovery#

Users most often report deeper sleep, and this is the effect with the most plausible physiology behind it. The body's largest natural growth hormone pulse happens during deep sleep, and compounds in this family interact with that rhythm.

What that looks like to a person is waking less and feeling more restored. No controlled sleep study of CJC-1295 has measured it, so this rests on self-report from people usually taking two compounds at once.

Anti-ageing#

The claim is a partial reversal of the decline in growth hormone that comes with age. The mechanism is straightforward; the leap is in assuming the decline is a defect worth correcting rather than a normal adjustment.

Growth hormone replacement in adults who are not deficient has been studied, and the results were modest. That is the closest evidence there is.

What the evidence shows#

Published human work confirms it does what it says mechanically. A study in healthy adults showed sustained increases in growth hormone and IGF-1 for several days after a single dose.

What has not been shown is that this produces the outcomes people want. No completed trial demonstrates changes in muscle, fat or ageing markers, because development did not continue to that stage.

The reported effects follow what raised growth hormone signalling does: fluid retention, tingling or numbness in the hands, joint aches, and occasional flushing after a dose.

The two versions sold under one name#

"CJC-1295 with DAC" includes a drug affinity complex that binds it to albumin in the blood and keeps it active for days. That is the version the published pharmacology was done on.

"CJC-1295 without DAC" is a different molecule that clears in about half an hour and is more accurately called modified GRF 1-29. It produces a short pulse rather than a sustained elevation, which is a materially different intervention.

They are sold under the same name at similar prices, so it is worth reading the fine print rather than the headline.

How it is taken#

Protocols circulating online describe subcutaneous injection, either once or twice weekly for the DAC version or daily before bed for the version without it.

Those schedules come from vendor documentation and accumulated community practice rather than from a trial, since no therapeutic dose has been established in healthy adults. Our guide to reconstituting a peptide vial covers the mechanics.

How it compares#

Against ipamorelin#

Ipamorelin works on the ghrelin receptor rather than the GHRH receptor, and produces a pulse rather than a sustained rise. The two are sold together on the argument that the effects are complementary, which has not been tested against either alone.

Against growth hormone itself#

Growth hormone bypasses the pituitary entirely. CJC-1295 asks it, which keeps some feedback control in play. That is a genuine mechanistic difference, and it is the basis of most of the interest in this family.

Common questions#

Which version should I be reading about?

The published human pharmacology used the DAC version. Most of the online protocol advice describes the version without it, which is a different molecule.

Is it the same as growth hormone?

No. It prompts the pituitary to release its own, which keeps feedback control in play.

Does it work without ipamorelin?

The published hormone data was generated with CJC-1295 alone, so it does something by itself. Whether the stack adds anything noticeable has not been tested.

How long does one dose last?

With DAC, several days. Without it, roughly half an hour.